Targeting inhibitors of apoptosis proteins suppresses medulloblastoma cell proliferation via G2/M phase arrest and attenuated neddylation of p21

Shu Mei Chen, Tzu Kang Lin, Yuan Yun Tseng, Chiao Hui Tu, Tai Ngar Lui, Shiang Fu Huang, Ling Ling Hsieh, Ying Ying Li

Research output: Contribution to journalArticle

Abstract

Medulloblastoma (MB) is the most common type of malignant childhood brain tumor. We previously showed that inhibitors of apoptosis proteins (IAP) small-molecule inhibitors (LCL161 or LBW242) combined with chemotherapy have synergistic antiproliferative effects on MB cells. The synergistic antitumor effects of combination treatments happen through induction of autophagy and caspase-3/7-activated apoptosis. Here, we investigated the effects of IAP inhibitors or silencing IAP on cell cycle regulation. We discovered that treatment with IAP inhibitors or their combination with conventional chemotherapy (vincristine or cisplatin), as well as RNAi knockdown of cIAP1/2 or XIAP arrested MB cells in the G2/M phase through downregulation of cyclin B1-CDK1 and cyclin A-CDK1/2. Among these three IAPs, only silencing cIAP1 expression enhanced p21 dependent-G2/M phase accumulation. IAP inhibitors reduced cIAP1 expression and increased p21 expression in time course experiments. Furthermore, cIAP1 can govern p21 proteasomal degradation via neddylation in lieu of ubiquitination. Inhibition of IAPs significantly abrogated cIAP1-mediated p21 degradation. We also observed an inverse correlation between nuclear cIAP1 and nuclear p21 expressions in MB tumor tissues. These findings provide new mechanistic evidence of the influence of IAP inhibitors on MB cell proliferation through disruption of the cell cycle.

Original languageEnglish
JournalCancer Medicine
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Inhibitor of Apoptosis Proteins
Medulloblastoma
G2 Phase
Cell Division
Cell Proliferation
Cell Cycle
Cyclin B1
Caspase 7
Drug Therapy
Cyclin A
Ubiquitination
Autophagy
Vincristine
RNA Interference
Brain Neoplasms
Caspase 3
Cisplatin
Down-Regulation
Apoptosis
Therapeutics

Keywords

  • Cell cycle
  • Inhibitors of apoptosis proteins
  • Medulloblastoma
  • Neddylation
  • P21

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Targeting inhibitors of apoptosis proteins suppresses medulloblastoma cell proliferation via G2/M phase arrest and attenuated neddylation of p21. / Chen, Shu Mei; Lin, Tzu Kang; Tseng, Yuan Yun; Tu, Chiao Hui; Lui, Tai Ngar; Huang, Shiang Fu; Hsieh, Ling Ling; Li, Ying Ying.

In: Cancer Medicine, 01.01.2018.

Research output: Contribution to journalArticle

@article{c9645b80857440c78a6733c0942830a8,
title = "Targeting inhibitors of apoptosis proteins suppresses medulloblastoma cell proliferation via G2/M phase arrest and attenuated neddylation of p21",
abstract = "Medulloblastoma (MB) is the most common type of malignant childhood brain tumor. We previously showed that inhibitors of apoptosis proteins (IAP) small-molecule inhibitors (LCL161 or LBW242) combined with chemotherapy have synergistic antiproliferative effects on MB cells. The synergistic antitumor effects of combination treatments happen through induction of autophagy and caspase-3/7-activated apoptosis. Here, we investigated the effects of IAP inhibitors or silencing IAP on cell cycle regulation. We discovered that treatment with IAP inhibitors or their combination with conventional chemotherapy (vincristine or cisplatin), as well as RNAi knockdown of cIAP1/2 or XIAP arrested MB cells in the G2/M phase through downregulation of cyclin B1-CDK1 and cyclin A-CDK1/2. Among these three IAPs, only silencing cIAP1 expression enhanced p21 dependent-G2/M phase accumulation. IAP inhibitors reduced cIAP1 expression and increased p21 expression in time course experiments. Furthermore, cIAP1 can govern p21 proteasomal degradation via neddylation in lieu of ubiquitination. Inhibition of IAPs significantly abrogated cIAP1-mediated p21 degradation. We also observed an inverse correlation between nuclear cIAP1 and nuclear p21 expressions in MB tumor tissues. These findings provide new mechanistic evidence of the influence of IAP inhibitors on MB cell proliferation through disruption of the cell cycle.",
keywords = "Cell cycle, Inhibitors of apoptosis proteins, Medulloblastoma, Neddylation, P21",
author = "Chen, {Shu Mei} and Lin, {Tzu Kang} and Tseng, {Yuan Yun} and Tu, {Chiao Hui} and Lui, {Tai Ngar} and Huang, {Shiang Fu} and Hsieh, {Ling Ling} and Li, {Ying Ying}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/cam4.1658",
language = "English",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Targeting inhibitors of apoptosis proteins suppresses medulloblastoma cell proliferation via G2/M phase arrest and attenuated neddylation of p21

AU - Chen, Shu Mei

AU - Lin, Tzu Kang

AU - Tseng, Yuan Yun

AU - Tu, Chiao Hui

AU - Lui, Tai Ngar

AU - Huang, Shiang Fu

AU - Hsieh, Ling Ling

AU - Li, Ying Ying

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Medulloblastoma (MB) is the most common type of malignant childhood brain tumor. We previously showed that inhibitors of apoptosis proteins (IAP) small-molecule inhibitors (LCL161 or LBW242) combined with chemotherapy have synergistic antiproliferative effects on MB cells. The synergistic antitumor effects of combination treatments happen through induction of autophagy and caspase-3/7-activated apoptosis. Here, we investigated the effects of IAP inhibitors or silencing IAP on cell cycle regulation. We discovered that treatment with IAP inhibitors or their combination with conventional chemotherapy (vincristine or cisplatin), as well as RNAi knockdown of cIAP1/2 or XIAP arrested MB cells in the G2/M phase through downregulation of cyclin B1-CDK1 and cyclin A-CDK1/2. Among these three IAPs, only silencing cIAP1 expression enhanced p21 dependent-G2/M phase accumulation. IAP inhibitors reduced cIAP1 expression and increased p21 expression in time course experiments. Furthermore, cIAP1 can govern p21 proteasomal degradation via neddylation in lieu of ubiquitination. Inhibition of IAPs significantly abrogated cIAP1-mediated p21 degradation. We also observed an inverse correlation between nuclear cIAP1 and nuclear p21 expressions in MB tumor tissues. These findings provide new mechanistic evidence of the influence of IAP inhibitors on MB cell proliferation through disruption of the cell cycle.

AB - Medulloblastoma (MB) is the most common type of malignant childhood brain tumor. We previously showed that inhibitors of apoptosis proteins (IAP) small-molecule inhibitors (LCL161 or LBW242) combined with chemotherapy have synergistic antiproliferative effects on MB cells. The synergistic antitumor effects of combination treatments happen through induction of autophagy and caspase-3/7-activated apoptosis. Here, we investigated the effects of IAP inhibitors or silencing IAP on cell cycle regulation. We discovered that treatment with IAP inhibitors or their combination with conventional chemotherapy (vincristine or cisplatin), as well as RNAi knockdown of cIAP1/2 or XIAP arrested MB cells in the G2/M phase through downregulation of cyclin B1-CDK1 and cyclin A-CDK1/2. Among these three IAPs, only silencing cIAP1 expression enhanced p21 dependent-G2/M phase accumulation. IAP inhibitors reduced cIAP1 expression and increased p21 expression in time course experiments. Furthermore, cIAP1 can govern p21 proteasomal degradation via neddylation in lieu of ubiquitination. Inhibition of IAPs significantly abrogated cIAP1-mediated p21 degradation. We also observed an inverse correlation between nuclear cIAP1 and nuclear p21 expressions in MB tumor tissues. These findings provide new mechanistic evidence of the influence of IAP inhibitors on MB cell proliferation through disruption of the cell cycle.

KW - Cell cycle

KW - Inhibitors of apoptosis proteins

KW - Medulloblastoma

KW - Neddylation

KW - P21

UR - http://www.scopus.com/inward/record.url?scp=85050482914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050482914&partnerID=8YFLogxK

U2 - 10.1002/cam4.1658

DO - 10.1002/cam4.1658

M3 - Article

AN - SCOPUS:85050482914

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

ER -